Head-To-Head Comparison: Caribou Biosciences (NASDAQ:CRBU) and BioStem Technologies (OTCMKTS:BSEM)

BioStem Technologies (OTCMKTS:BSEM) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Analyst Ratings

This is a summary of current ratings for BioStem Technologies and Caribou Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioStem Technologies	0	1	0	1	3.00
Caribou Biosciences	1	0	3	1	2.80

BioStem Technologies presently has a consensus price target of $9.00, indicating a potential upside of 117.39%. Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 525.00%. Given Caribou Biosciences’ higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than BioStem Technologies.

Insider & Institutional Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares BioStem Technologies and Caribou Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioStem Technologies	$292.21 million	0.25	-$28.56 million	($1.60)	-2.59
Caribou Biosciences	$11.16 million	11.91	-$148.12 million	($1.08)	-1.15

BioStem Technologies has higher revenue and earnings than Caribou Biosciences. BioStem Technologies is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioStem Technologies and Caribou Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioStem Technologies	N/A	N/A	N/A
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Risk and Volatility

BioStem Technologies has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Summary

Caribou Biosciences beats BioStem Technologies on 8 of the 14 factors compared between the two stocks.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.